Epithelial ovarian cancer with CD117 phenotype is highly aggressive and resistant to chemotherapy. Issue 10 (14th July 2015)

• Record Type: Journal Article
• Authors: Conic, Irena; Stanojevic, Zorica; Jankovic Velickovic, Ljubinka; Stojnev, Slavica; Ristic Petrovic, Ana; Krstic, Miljan; Stanojevic, Marko; Bogdanović, Dragan; Stefanovic, Vladisav
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 41:Issue 10(2015:Oct.)
• Page Start: 1630
• Page End: 1637
• Publication Date: 2015-07-14
• Subjects: Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.12758
• Languages: English
• ISSNs: 1341-8076

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jog12758-sec-0002" sec-type="section"> <title>Aim</title> <p>CD117 expression has a pathogenic role in many malignancies, including ovarian carcinoma. The aim of the present study was to examine the correlation of stemness‐associated marker CD117 with the clinicopathologic features of epithelial ovarian cancer and patient survival.</p> </sec> <sec id="jog12758-sec-0003" sec-type="section"> <title>Material and Methods</title> <p>The analysis included 240 primary ovarian carcinomas (OC) diagnosed during the period from 2005 to 2011 in the region of South Serbia. Age, pathohistological characteristics, presence and size of residual tumor, choice of therapy and response to the therapy were studied.</p> </sec> <sec id="jog12758-sec-0004" sec-type="section"> <title>Results</title> <p>Residual tumors were more frequently present in the patients with positive CD117 expression (18.1% vs 8.0%; <italic>P</italic> < 0.05). Chemotherapy according to paclitaxel/carboplatin protocol was more frequent in the patients with positive CD117 expression (70.9% vs 54.2%; <italic>P</italic> < 0.05), while carboplatin monotherapy was more frequent in the patients with negative CD117 expression (18.0% vs 6.4%; <italic>P</italic> < 0.05). Median survival time in patients with CD117‐positive mucinous and endometrioid OC was significantly shorter, at 20 and 26.8 months, respectively. Median survival in serous OC was not related to CD117 expression.</p> </sec> <sec id="jog12758-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Residual tumors and chemotherapy treatment were more frequent in patients with positive CD117 expression. The outcome was dependent on the type of OC; a worse outcome, including a shorter survival, was documented in the mucinous and endometrioid OC cases.</p> </sec> </abstract>